Benzinga | Dec 13, 2021 06:02AM EST

Lilly And Foghorn Announce Strategic Collaboration For Novel Oncology Targets Using Foghorn's Proprietary Gene Traffic Control Platform; Foghorn To Receive $300M Upfront And An Equity Investment By Lilly Of $80M At $20/Share

- Establishes co-development and co-commercialization agreement on Foghorn's selective BRM program and an additional undisclosed program



- Collaboration includes three additional discovery programs

- Foghorn to receive $300 million upfront and an equity investment by Lilly of $80 million at $20 per share